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Neutrophil Elastase (NE) is a pro-inflammatory protease pres-
ent at higher than normal levels in the lung during inflammatory
disease. NE regulates IL-8 production from airway epithelial cells
and can activate both EGFR and TLR4. TACE/ADAM17 has been
reported to trans-activate EGFR in response to NE. Here, using
16HBE14o-humanbronchial epithelial cellswedemonstrateanew
mechanism by which NE regulates both of these events. A high
molecular weight soluble metalloprotease activity detectable only
in supernatants fromNE-treatedcellsbygelatinandcaseinzymog-
raphywas confirmed to bemeprin alpha byWestern immunoblot-
ting. In vitro studies demonstrated the ability of NE to activate
meprin alpha, which in turn could release soluble TGF and
induce IL-8 production from 16HBE14o- cells. These effects were
abrogated by actinonin, a specific meprin inhibitor. NE-induced
IL-8 expression was also inhibited by meprin alpha siRNA.
Immunoprecipitation studies detected EGFR/TLR4 complexes in
NE-stimulatedcellsoverexpressingthesereceptors.Confocal stud-
ies confirmed colocalization of EGFR and TLR4 in 16HBE14o-
cells stimulated with meprin alpha. NFB was also activated via
MyD88 in these cells by meprin alpha. In bronchoalveolar lavage
fluid from NE knock-out mice infected intra-tracheally with
Pseudomonas aeruginosa meprin alpha was significantly
decreased compared with control mice, and was significantly
increased and correlated with NE activity, in bronchoalveolar
lavage fluid from individuals with cystic fibrosis but not healthy
controls. Thedata describe a previously unidentified lungmetallo-
proteasemeprin alpha, and its role inNE-inducedEGFRandTLR4
activation and IL-8 production.
Neutrophil elastase (NE)4 is a 29-kDa serine protease that is
stored in the azurophilic granules of neutrophils (1). The main
intracellular physiological function of NE is the degradation of
foreign organic molecules phagocytosed by neutrophils. NE is
well documented as one of numerous neutrophil proteases
responsible for destroyingmicrobes (2, 3). Its principal target is
elastin (4); however, it can also degrade extracellular matrix
proteins, collagen types I-IV, proteoglycan, fibronectin, platelet
IIb/IIIa receptor, complement receptor, thrombomodulin (5),
lung surfactant proteins (6), cadherin (7), and cleave comple-
ment factors, immunoglobulin, protease inhibitors, and several
proteases (8). Neutrophils are the primary cell lineage that pro-
duces NE and are a key immune cell involved in pro inflamma-
tory lung disorders. A high neutrophil burden has been linked
to an increase in inflammation within the lung (9), and NE has
been implicated in several diverse inflammatory lungs disor-
ders including cystic fibrosis (10).
Previous studies have identified in part the intracellular sig-
naling pathway regulated by NE (11) and established that NE
can induce IL-8 via TLR4 (12). Other studies have demon-
strated partial inhibition of NE-induced IL-8 production by
using specific inhibitors of TLR signaling in airway epithelial
cells (12, 13). NE is also likely to regulate expression of IL-8 and
other genes by alternative mechanisms.
In addition to TLR4, another receptor of interest which NE
has been shown to trans-activate, is EGFR (14). EGFR plays a
key role in many cellular processes (15) and is important for
mucin production from airway epithelial cells (16) and in sus-
taining neutrophil inflammation (17). EGFR is a transmem-
brane protein consisting of an extracellular ligand-binding
domain to which EGFR ligands such as transforming growth
factor  (TGF) and epidermal growth factor (EGF) bind for
activation. Its intracellular domain consists of a tyrosine kinase
domain. Upon activation via ligand binding, EGFR is phospho-
rylated on key tyrosine residues and docking of signal transduc-
ers can occur (18). In addition to direct activation by EGFR
ligands, EGFR can also be trans-activated by other stimuli such
as lipoteichoic acid (19), other TLR agonists (20) and NE (16,
21). The mechanism of NE-induced Mucin (MUC5AC) pro-
duction via EGFR in NCI-H292 cells, an epithelial line derived
from a mucoepidermoid pulmonary carcinoma has been
documented (16) with TNF--converting enzyme (TACE/
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ADAM17) shown to be involved in EGFR ligand generation.
EGFR has also been implicated in NE-induced IL-8 produc-
tion in lung epithelial cells (22); however, the in vivo biolog-
ical significance of TACE in these events remains to be elu-
cidated. Interestingly other metalloproteases in addition to
TACE are reported to have a role in activation of EGFR (23).
We set out to understand in greater detail how NE trans-
activates EGFR in human bronchial epithelial cells and to inte-
grate this new knowledge with our current understanding of
theNEmechanism of action on IL-8 expression.We postulated
that a novel metalloprotease that shares redundancy with
TACE is activated by NE in bronchial epithelial cells. Our aim
was to identify such a protease, determine its biological activity
against EGFR and TLR and elucidate its role in NE-induced
activation of NFB and regulation of IL-8 gene expression.
Here we demonstrate the involvement of meprin alpha, a pre-
viously unidentified target of NE, in the NE-induced EGFR/
TLR4 inflammatory pathway in human bronchial epithelial
cells.
MATERIALS ANDMETHODS
Chemicals—Chemicals and reagents were purchased from
Sigma unless indicated otherwise.
Cell Culture and Treatment—16HBE14o- cells are an SV40-
transformed human bronchial epithelial cell line and were
obtained as a gift fromD. Gruenert (University of Vermont). The
cells were cultured in minimal essential medium (MEM) supple-
mented with 10% FCS, 1% L-glutamine, 1% penicillin/streptomy-
cin, (Invitrogen). Thehuman embryonic kidney cell line,HEK293,
(ECACC-85120602) was cultured in Eagle’s Minimal Essential
Medium (EMEM, Invitrogen) supplemented with 10% FCS, 1%
L-glutamine, 1% penicillin/streptomycin, 1% NEAA (Invitrogen).
293-hTLR4-HA cells, an isolated clone of HEK293 cells stably
transfectedwithhumanHA-taggedTLR4(InvivoGen,SanDiego),
were cultured in DMEM, 10% FCS, 10 g/ml blastocidin S
(InvivoGen), and 1% penicillin/streptomycin.
NE Activity Assay—NE activity was quantified prior to all
experiments using the NE substrate (0.5 mM N-methoxysucci-
nyl-Ala-Ala-Pro-Val-p-nitroanilide).  absorbance units (2
min) at 405 nmwere recorded and comparedwith anNE stand-
ard of known activity.
Zymography—Zymographywas performed on 150l serum-
free medium from untreated, EGF- or NE-treated cells (1 
106). Samples of human ormurine BALF containing 400 ng or 2
g of protein, respectively, were treated for 10min with sample
buffer (0.25% bromphenol blue, 50 mM Tris, pH 7.5, 40% glyc-
erol, and 1% SDS) and were electrophoresed on a 7% SDS-poly-
acrylamide gel containing gelatin or casein (1 mg/ml). After
electrophoresis, the gels were incubated in 50 mM Tris, pH 7.5,
5 mM CaCl2, 1 M ZnCl2, and 2.5% (v/v) Triton X-100 for 30
min, washed in the same buffer without Triton X-100 for 5min
and incubated at 37 °C overnight in the same buffer supple-
mented with 1% (v/v) Triton X-100. The gels were stained with
0.125% Coomassie Blue and washed with 10% acetic acid and
40% methanol in water.
RT PCRAnalysis forMeprin Gene Expression—RNAwas iso-
lated from 16HBE14o- and HEK293 cells in TRI reagent, and
RNA was extracted. RNA (2 g) was reverse-transcribed into
cDNA, and 2 l was amplified with 1.25 units of TaqDNA po-
lymerase, 1 PCR buffer, and 10 mM dNTPs (Promega) in a
50-l volume containing 100 pmol each of the following prim-
ers: Meprin alpha: 5-GAAATCCAGAAATGGCCTGA-3, 5-
TGGAAATGTTCTGTCCCACA-3; -actin: 5-GGGTACA-
TGGTGGTGCCG-3, 5-GCCGGGAAATCGTGCGTG-3.
After a hot start, the amplification profile was 45 cycles of 1
min denaturation at 95 °C, 1 min annealing at 50 °C, and 1 min
extension at 72 °C. RT-PCR amplification of meprin A and
-actin generated products of 242 bp and 402 bp, respectively.
PCR products were resolved on a 1% agarose gel containing 0.5
g/ml ethidium bromide.
Microscopy—Immunofluorescence microscopy was per-
formed as described previously (24) with some alterations.
16HBE14o- cells (1 105) were cultured overnight in chamber
slides (Lab-Tek). Cells were washed and fixed with 4% (w/v)
paraformaldehyde for 10 min, permeabilized with 0.2% (v/v)
TritonX-100 in PBS for 10min and blockedwith 10mMNaBH4
for 1 h. Cells were incubated with rabbit anti-meprin alpha (25)
overnight at 4 °C, or mouse anti TLR4 FITC labeled (Abcam)
and EGFR (SCBT) antibody for 1 h, washed, and incubatedwith
goat anti-rabbit IgG secondary antibody Rhodamine labeled
(Abcam) at 5 g/ml for 1 h. Controls for this experiment
included cells alone, Rabbit IgG isotype control (R&D Systems)
and those exposed to secondary antibody only.
Meprin Activity Assay—Activity assays were carried out
using the fluorogenic peptide substrate Mca-YVADAPK-
(Dnp)-OH according to the manufacturer’s direction (R&D
Systems). Briefly, to activatemeprin alpha, the enzyme (100 ng)
was incubated with 0.1 ng of trypsin or 100 nM of NE in TCNB
(50 nM Tris, 10 mM CaCl2, 0.15 M NaCl, 0.05% Brij 35, pH 7.5)
for 3 h at 37 °C. Trypsin andNEwere inactivatedwithAEBSF (1
mM) or CMK (5 M), respectively, to prevent turnover of the
meprin substrate, and fluorescence was quantified at 320 nm
excitation and 450 nm emission after 60 min.
IL-8 ELISA—16HBE14o- cells (1  105/well) were left
untreated or treated for 1 h with 5 g/ml EGFR ligand neutral-
izing antibody (R&D Systems), 500 nM AG1478 (Calbiochem),
2 g of EGFR neutralizing antibody (Oncogene Ab-3), or 100
M actinonin followed by EGF, TGF, HBEGF, or NE for 4 h.
Medium was removed and used in an IL-8 ELISA (R&D Sys-
tems). 5 M MetOSuc-Ala-Ala-Pro-Val-chloromethyl ketone
(CMK) was added to NE-treated media to prevent active NE
from interfering with IL-8 measurement.
TGF ELISA—Cells were untreated or treated with vehicle
(DMSO) or actinonin (100M) for 1 h followedbyNE, activated
recombinant meprin alpha, or media for 4 h. For all experi-
ments EGFR was blocked for 30 min with 2 g/ml anti-EGFR
neutralizing antibody (Calbiochem) prior to agonist treatment.
Supernatants were collected, and TGF was measured via
ELISA (R&D Systems) (14).
Bronchoalveolar Lavage Fluid (BALF)—NE gene-targeted
micewere generated, as previously described (2). NE knock-out
mice (n 3) and their wild-type littermates (n 3) were intra-
nasally challenged with PBS (50 l) or PBS containing Pseudo-
monas aeruginosa H103 (4.8  106 CFUs). Twenty-four hours
later, BALF was collected (26).
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BALF from individuals with CF (n 11) or healthy controls
(n 10) was collected following informed consent using a pro-
tocol approved by Beaumont Hospital Ethics Committee (13).
Samples were filtered through gauze, centrifuged at 1,000  g
for 10 min, and cell-free supernatants were aliquoted and
stored at80 °C.
EGFR trans-Activation—16HBE14o- cells were seeded at 1
106 on a 6-well plate for 24 h in supplementedMEM.Cells were
serum-starved in serum-free MEM for 2 h prior to stimulation
and then left untreated (control) or stimulated with EGF (R&D
systems) (10 ng/ml) or 100 nMNE (Elastin Products,MO) for 10
min. Medium was removed, centrifuged, and stored at20 °C.
Cells were washed with PBS and lysed using a radioimmune
precipitation assay buffer (10 mM Tris, pH 7.4, 100 mM NaCl, 1
mM EDTA, 1 mM EGTA, 1 mM NaF, 20 mM Na4P2O7, 2 mM
Na3VO4, 1% Triton X-100, 10% glycerol, 0.1% SDS, and 0.5%
deoxycholate) containing protease inhibitor tablets (RocheUK)
and 1mM phenylmethylsulfonyl fluoride. Cell lysates were clar-
ified by centrifugation and were used in EGFR and EGFR
[pY1173] ELISAs (BIOSOURCE CA) according to the manu-
facturer’s instructions.
Transfections—16HBE14o- cells were uniformly co-trans-
fected for 24 h with a constitutive luciferase reporter gene con-
struct, pRLSV40 (100 ng, Promega) and an empty vector
pCDNA3.1 (150 ng, Invitrogen) or the same vector carrying a
gene encoding a dominant negative functionally inactive
MyD88 (150 ng) as previously reported (12, 13) using Gene
Juice (Novagen). Cells were left untreated or stimulated as indi-
cated. NFB activation was assessed (see below) or superna-
tants were retained after 24 h for IL-8 ELISA, and cells were
lysed with Reporter Lysis buffer (Promega) and quantified by
luminometry to determine transfection efficiencies (Wallac
Victor2, 1420 multilabel counter). IL-8 protein production was
calculated as pg per light unit (L.U.).
293-hTLR4-HA cells (5 106) were transfected for 48 hwith
an empty vector or a plasmid expressing human EGFR (1 g,
UpstateCat. 21–176) and left untreated or treatedwith agonists
(as described) for 10min prior to immunoprecipitation with an
anti-HA tag (InvivoGen) or an anti-EGFRmonoclonal antibody
(sc-120, SantaCruz Biotechnology) and immunodetectionwith
either anti-HA tag or anti-EGFR monoclonal antibodies.
NFB Assays—NFB activation was assessed by three meth-
ods. (i) Cells (5  105) were co-transfected as described above
with an (NFB)5-luciferase reporter plasmid and pRLSV40 for
24 h then stimulated with meprin alpha for 6 h. Relative lucif-
erase production was quantified by luminometry. (ii and iii)
Cells were co-transfected with pCDNA3 or the MyD88
expression plasmid for 24 h, then stimulated with meprin for
1 h. Nuclear extracts were prepared and examined by Western
blotting using p65 and TBP antibodies (Santa Cruz Biotechnol-
ogy), and p65/TBP ratios were quantified by densitometry or
assessed 1 h post-stimulation with meprin using TransAM
NFB p65 (Actif Motif) as recommended by the manufacturer.
RNAi—16HBE14o- cells (5  105) were transfected with 50
nM of a siRNA-targeting Meprin alpha (siRNA ID 104082,
Ambion) or a scrambled control duplex (Silencer GAPDH
siRNA Control Ambion) for 24 h. Cells were placed in serum-
free medium and stimulated with NE (100 nM for 24h). Total
RNA was extracted for qRT-PCR using the Roche LC480 and
SYBR Green I Master withMeprin alpha or GAPDH (Forward:
5-CATGAGAAGTATGACAACAGCCT-3, Reverse: 5-
AGTCCTTCCACGATACCAAAGT-3) primers (MWG Bio-
tech) to quantify knockdown. Cell supernatants were retained
for IL-8 ELISA.
Statistical Analysis—Data were analyzed with the PRISM 3.0
software package (GraphPad, San Diego, CA). Results are
expressed as the mean S.E. and were compared by Student’s
t test or analysis of variance. Differences were considered sig-
nificant at p 0.05.
RESULTS
Identification of Novel Protease Activity from 16HBE14o-
Cells Treated with NE—In our search for novel metallopro-
teases activated by NE, we analyzed supernatants from
untreated, EGFR ligand- and NE-treated 16HBE14o- cells by
zymography. Fig. 1 shows that a high molecular weight gelatin-
FIGURE 1. Identification of metalloproteases in media of control and
stimulated bronchial epithelial cells. 16HBE14o- cells (1  106) were
untreated (control) or treated with EGF (20 ng/ml) or NE (100 nM) in serum-
freemedia for 10min. Medium from treated cells (5g) was electrophoresed
on:A, a gelatin zymogram; B, a casein zymogram; orC, electrophoresedunder
non-reducing conditions in SDS-PAGE, transferred to nitrocellulose, and
probed with an anti-meprin alpha antibody.
balt3/zbc-bc/zbc-bc/zbc04608/zbc5554-08z xppws S1 21/10/08 12:24 4/Color Figure(s) F2,7 ARTNO: M803732200
NE Activates EGFR and TLRA viaMeplin
31738 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 283•NUMBER 46•NOVEMBER 14, 2008
F1
ase activity, above 175 kDa, was detectable in the NE-treated
supernatants but was absent from the control and EGF-treated
samples (Fig. 1A).
Examination of protease activity using a casein zymogram
showed this high molecular weight NE-induced gelatinase also
had caseinase activity of the same size, whichwas not present in
the control, or EGF-treated samples (Fig. 1B). Based on these
properties and its migration in non-reducing PAGE, this indi-
cated that it may bemeprin; therefore, we performed immuno-
blot analysis using an anti-meprin alpha antibody. An immuno-
reactive band of the same size was detected in the NE-treated
samples but was not detectable in the control or EGF-treated
samples (Fig. 1C). No signals were detected in any of the sam-
ples at 175 kDa using MMP2 or MMP9 antibodies (data not
shown).
Detection of Meprin Alpha Expression in 16HBE14o- Cells—
To verify meprin alpha expression by 16HBE14o- cells
RT-PCR, Western blotting, and immunofluorescence confocal
microscopy was performed (Fig. 2). Meprin alpha mRNA was
detected in 16HBE14o- cells and HEK293 cells, a human
embryonic kidney cell line known to express meprin alpha (Fig.
2A). Meprin alpha has aMr of 84.4 kDa but because of glycosy-
lationmigrates with amolecular weight of90 kDa in reducing
SDS-PAGE (27). Fig. 2B shows a Coomassie Blue-stained gel of
meprin alpha immunoprecipitated from16HBE14o- cells using
a monoclonal antibody (lane 3). Recombinant meprin alpha
was used as a control (lane 1) andmolecular weightmarkers are
in lane 2. A duplicate gel was transferred to a nitrocellulose
membrane and probed with a rabbit polyclonal anti-meprin
alpha antibody and an immunoreactive signal of the correct
molecular weight was evident in the immunoprecipitate (Fig.
2C). Immunofluorescence and confocal microscopy were per-
formed to visualize the location of meprin alpha in 16HBE14o-
cells using a goat polyclonal anti-human meprin alpha anti-
body. As shown in Fig. 2D, meprin alpha expression was
detected peri-nuclear and also on the cell membrane.
Meprin Alpha Activated by NE Can Induce IL-8 Expression
and Release TGF from 16HBE14o- Cells—Trypsin is a potent
activator of meprin alpha. We examined whether NE, like
trypsin, could activate meprin alpha using a fluorimetric
activity assay. A recombinant inactive form of meprin alpha
was incubated with trypsin or NE, the serine proteases were
inactivated, and meprin activity was measured using a sub-
strate that had meprin specificity. Fig. 3A shows that both
trypsin andNE can activate meprin to similar levels (p 0.01
and p  0.02, respectively).
Having established that NE can activate meprin alpha we
next evaluated whether meprin alpha, like NE, can induce IL-8
production from 16HBE14o- cells. Here cells were either
untreated, treated with NE or active meprin, and IL-8 levels
were quantified in cell supernatants. Fig. 3B shows that meprin
alpha induced greater than 2-fold increase in IL-8 secretion
compared with control cells (p 	 0.001) similar to NE (p 	
0.001 versus control).
NE can generate soluble TGF from 16HBE14o- cells (Fig.
3C, p  0.03). We investigated the effect of meprin alpha on
proTGF. Cells were left untreated or treated with NE, meprin
alpha, or supernatants fromNE-treated 16HBE14o- cells (from
which TGF had been depleted and that had also been treated
with a specificNE inhibitor). These supernatants had gelatinase
activity (data not shown). TGF levels in the cell supernatants
were quantified by ELISA. Fig. 3C shows that like NE, meprin
alpha or NE-treated supernatants leads to release of soluble
TGF (p 0.01 and 0.01, respectively).
Inhibition of Meprin Alpha Can Impair IL-8 Production in
NE-stimulated Bronchial Epithelial Cells—NE-induced IL-8
expression is TGF-dependent and can be inhibited using a
TGF-neutralizing antibody (Fig. 4A). Neutralizing antibodies
to EGF and HBEGF have no effect. EGFR is also involved in
NE-induced IL-8 expression. NE can trans-activate EGFR (Fig.
4B) and inhibition of EGFR usingAG1478 or an EGFR antibody
impairs NE-induced IL-8 expression (Fig. 4C).
Actinonin is a naturally occurring hydroxamate that is the
most effective inhibitor of meprin alpha (35–38). We investi-
gated its effects onNE-induced IL-8 andTGF production.We
performed a dose response of actinonin (0–100M) investigat-
FIGURE 2. Detection of meprin alpha mRNA and protein in 16HBE14o-
cells.A, total RNAor cDNA from16HBE14o- andHEK293 cellswas used in PCR
reactions with meprin alpha or -actin primers, as indicated. Products were
visualizedon a 1%agarosegel.B, Coomassie Blue-stained SDS-PAGofmeprin
alpha (lane 1), molecular weight marker (lane 2), and a meprin alpha immu-
noprecipitate from a whole cell lysate of 16HBE14o- cells (lane 3, arrow indi-
cates IP). C, Western blot analysis of a duplicate gel probed with rabbit anti-
meprinpolyclonal antibody.D, fixedandpermeabilized16HBE14o- cellswere
incubatedwithprimary antibody against humanmeprin alpha andvisualized
by fluorescence confocal microscopy.
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ing its effect onNE-induced IL-8 expression in 16HBE14o- cells
(data not shown), and from this selected 100 M as the most
effective inhibitory dose. Actinonin effectively inhibited
meprin alpha activity induced by either trypsin or NE (p 	
0.001 for both) (Fig. 5A) and also significantly inhibited NE-in-
duced IL-8 (Fig. 5B) and TGF (Fig. 5C) production from
16HBE14o- cells (#, p 	 0.001). To confirm that inhibition of
NE-induced IL-8 expression by actinonin ismediated via block-
FIGURE 3. Activation of meprin alpha and meprin alpha induction of
TGF and IL-8. A, inactive recombinant meprin alpha (100 ng) was exposed
to trypsin (0.1 ng) or NE (100 nM) for 3 h. Meprin activity was quantified at 320
nm/405 nm (* versus control). B, 16HBE14o- cells (1  105) were stimulated
with NE (100 nM, 4 h) or activated meprin alpha (100 nM, 4 h). IL-8 levels in
supernatants were quantified by ELISA (* versus control). C, CMK (5 M) was
added to cell-free media from 16HBE14o- cells treated with NE (100 nM, 10
min) and used to stimulate fresh 16HBE14o- cells (1 105, treated with EGFR
ligand-neutralizing antibody (2 g/ml, 1 h)). TGF- levels in supernatants
werequantifiedbyELISA.NE (100nM, 4h) andmeprin alpha (100nM, 4h)were
also used (* versus control).
FIGURE 4.NE-induced IL-8 occurs via trans-activation of EGFRgeneration
of TGF in humanbronchial epithelial cells. 16HBE14o- cells were (A) incu-
bated with EGF, TGF, or HBEGF neutralizing antibodies (2 g, 1 h), then
stimulated with NE (100 nM, 4 h) in serum-free media. IL-8 levels in superna-
tants were quantified by ELISA (* versus control, # versus agonist), B, stimu-
lated with EGF (10 ng/ml) or NE (100 nM) for 10 min and total and phosphor-
Y1173 levels were quantified by ELISA (* versus control). C, 16HBE14o- cells
were treated with medium or DMSO (vehicle), AG1478 (500 nM, hatched bar),
or an EGFR-neutralizing antibody (2 g, black bar) for 1 h prior to treatment
with NE (100 nM, 4 h) and IL-8 levels in supernatants were quantified by ELISA
(* versus control, # versus agonist).
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ing meprin alpha, we next performed siRNA experiments
knocking down meprin alpha (98.6% knockdown). Fig. 5D
shows that NE-induced IL-8 expression is abrogated by a
meprin alpha siRNA.
Presence of Meprin Alpha in Bronchoalveolar Lavage Fluid
(BALF) in Lung Inflammation Correlates with NE—We next
assessed the role of meprin alpha in vivo. Meprin activity was
examined in BALF of NE knock-out and wild-type mice
infected with Pseudomonas aeruginosa. Gelatin zymography
detected a high molecular weight gelatinase activity above 175
kDa that was present in higher quantities in wild type (Fig. 6A,
lanes 1–3) versus NE knock-out mice (lanes 4–6).
We also evaluated bronchoalveolar lavage fluid samples from
individuals with cystic fibrosis (CF) and healthy controls for
meprin activity. CF is an inflammatory lung condition associ-
ated with high levels of active NE in the lung. Fig. 6B shows
evidence of a high molecular weight gelatinase activity indica-
tive of meprin alpha in 11 of 11 BALF samples fromCF individ-
uals. No gelatinase activity was detectable in 10 control BALF
samples under the same conditions. Fig. 6C shows the corre-
sponding NE activities per g of protein in each of the BALF
samples (p 0.0002 for normal versus CF BALF). The gelatin-
ase activity in 2 representativeCFBALF sampleswas confirmed
to be meprin alpha by Western immunoblotting (Fig. 6D).
Meprin Induces Co-localization of EGFR and TLR4—We
investigated how the NE-Meprin-TGF-EGFR-IL-8 pathway
reported here integrates with our previous reports demonstrat-
ing the NE-TLR4-MyD88-IL-8 pathway (11, 28). In Fig. 7A we
evaluated the effect ofMyD88, an inhibitor of TLR4 signaling,
on NE- and TGF-induced IL-8 production. 16HBE14o- cells
were transfected with an empty vector or aMyD88 transgene,
stimulatedwithNE,TGF, or LPS, and IL-8 protein production
per transfected cell was quantified. NE, TGF, and LPS all sig-
nificantly increased IL-8 expression. MyD88 inhibited not
only NE-induced IL-8 expression but also that induced by
TGF and LPS, suggesting that EGFR and TLR4 may interact.
We investigated this by performing immunoprecipitations
from HEK293 cells expressing TLR4 and EGFR. Fig. 7B shows
TLR4 expression (lane 1) in untreated 293-hTLR4-HAcells and
EGFR expression only in those transfected with an EGFR
expression plasmid (lanes 2 and 3). Immunoprecipitations
using an anti-EGFR antibody followed by Western immuno-
blotting with either anti-HA (to detect TLR4) or anti-EGFR
antibodies detected a weak interaction between TLR4 and
EGFR in untreated cells (Fig. 7C, lanes 1 and 4) as indicated by
the weak EGFR signal (lane 4). Treatment with NE (lanes 2 and
5) or EGF (lanes 3 and 6) enhanced the formation of this com-
plex confirming that EGFR can be co-immunoprecipitated in a
complex with TLR4 in agonist-treated cells. We confirmed the
observations of these overexpression studies in real cells by
confocal microscopy. Fig. 7D shows that in 16HBE14o- cells
stimulated with meprin alpha endogenously expressed TLR4
and EGFR co-localize. NE induces a similar effect but also dam-
ages the integrity of the monolayer. LPS treatment did not
induce co-localization of EGFR and TLR4 in 16HBE14o- cells
(data not shown).
Meprin Activates NFB via MyD88—Finally we investigated
the ability of meprin alpha to activate NFB. Fig. 8A shows
FIGURE5.Actinoninandknockdownofmeprinalpha inhibitsNE-induced
TGF and/or IL-8 production. A, inactive recombinant meprin alpha (100
ng) was exposed to trypsin (0.1 ng) or NE (100 nM) for 3 h. Actinonin (100M)
was added as indicated. Meprin activity was quantified at 320 nm/405 nm (*
versus control, # versuswithout actinonin). Cells (B, 1 105 or C, 1 106) were
stimulated with NE (100 nM) and/or 100 M actinonin (30 min) and (B) IL-8
levels or (C) TGF levels in supernatants were quantified by ELISA (* versus
control, # versus agonist). D, cells (5 105) transfected with meprin alpha or
scrambled (50 nM) siRNAs were stimulated with NE (100 nM, 6 h). RNA was
isolated and used for qRT-PCR and relative IL-8 levels in supernatants are
shown (* versus untreated cells). Data are representative of three independ-
ent experiments performed in triplicate.
FIGURE6.Analysis ofmeprin inBALF samples.A, wild-typeBALF (lanes 1–3)
andNE/BALF (lanes 4–6)wasapplied toagelatin zymogram(meprinactiv-
ity). B, CF (n  11) and normal BALF (n  10) samples (400 ng/lane) were
applied to a gelatinase zymogram. Lane 11 in normal BALF is blank. C, NE
activity per g of protein was quantified in CF BALF and normal BALF sam-
ples. D, two representative CF BALF samples were electrophoresed under
non-reducing conditions on SDS-PAGE, transferred to nitrocellulose, and
probed with an anti-meprin alpha antibody (* versus normal).
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that meprin alpha (75 nM) induces expression from an
NFB-luciferase reporter plasmid as potently as NE (100
nM). Meprin alpha also induced nuclear localization of NFB
in an MyD88-dependent manner. Fig. 8B shows relative p65
nuclear localization, normalized to the nuclear marker
TATA-binding protein (TBP), in cells transfected with an
empty vector or a MyD88 transgene. p65 nuclear localiza-
tion was inhibited by MyD88. Fig. 8C shows the dose-de-
pendent effect of meprin alpha on NFB activation using a
p65 nuclear localization ELISA. The meprin alpha effect is
inhibited by MyD88. Meprin alpha-induced IL-8 expres-
sion is also inhibited in a similar way (Fig. 8D).
DISCUSSION
In this study, we set out to identify a new airway epithelial
cell-derived metalloprotease that can participate in NE-in-
duced IL-8 production via EGFR. Our data demonstrate that
human airway epithelial cells express meprin alpha and that
NE, an abundant serine protease in inflammed and infected
airways, can activatemeprin alpha rendering it capable of cleav-
ing proTGF. This is turn leads to trans-activation of EGFR
inducing it to co-localize with TLR4.We also show thatmeprin
alpha can activate NFB in a MyD88-dependent manner and
induce IL-8 expression in 16HBE14o- cells.Overall we establish
the presence and activity of meprin alpha in NE-rich samples
both in vitro and in vivo and demonstrate thatmeprin alpha has
the capability of inducing IL-8 via EGFR. Together, the data
identifymeprin alpha as a newbiologically active target ofNE in
the airways and implicate it as a potential therapeutic target for
inflammatory lung disease.
The principal finding from this study is the identification of
meprin alpha as an NE-activated metalloprotease capable of
FIGURE 7. Meprin and NE induce co-localization of EGFR and TLR4.
A, 16HBE14o- cells (1 105) were co-transfected for 24 hwith pCDNA3.1 (EV)
or a MyD88 expression plasmid and a constitutive luciferase reporter
plasmid. Cells were stimulated for 24 h with NE (100 nM), TGF (10 ng/ml),
or LPS (10 g/ml) and IL-8 protein production was quantified by ELISA.
Units are represented as IL-8 pg/light unit. B, 293-hTLR4-HA cells (5 106)
were left untreated (lane 1) or transfected for 48 h with an empty vector
(lane 2) or a plasmid expressing human EGFR (lane 3). Immunoprecipita-
tions and Western immunoblotting were performed as indicated. C, 293-
hTLR4-HA cells (5  106) transfected with a plasmid expressing human
EGFR were left untreated (lanes 1 and 4) or treated for 10 min with NE (100
nM, lanes 2 and 5) or EGF (10 ng/ml, lanes 3 and 6) prior to immunoprecipi-
tationwith an anti-EGFRmonoclonal antibody followed by immunodetec-
tionwith anti-HA (lanes 1–3) or anti-EGFR (lanes 4–6) monoclonal antibod-
ies for TLR4 and EGFR, respectively. D, 16HBE14o- cells were left untreated
or stimulated with meprin alpha (75 nM) or NE (100 nM) for 30 min, labeled
with anti-TLR4 (red) and anti-EGFR (green) or isotype antibodies, and visu-
alized by fluorescence confocal microscopy. White arrows indicate co-lo-
calization of EGFR and TLR4.
FIGURE 8. MyD88 inhibits meprin-induced NFB activation and IL-8
expression. 16HBE14o- cells (A) (1 106) were co-transfected for 24 hwith a
constitutive luciferase reporter plasmid pRLSV40 and an inducible (NFB)5-
luciferase reporter plasmid then stimulated for 6 hwithmeprin alpha (75 nM)
or NE (100 nM). Relative NFB activity is shown (* versus unstimulated cells)
(B–D) (1  106) were co-transfected for 24 h with a constitutive luciferase
reporter plasmid pRLSV40 and pCDNA3.1 (EV) or a MyD88 expression plas-
mid. Cells were stimulated for 1 h (B and C) or 6 or 24 h (D) with meprin alpha
(75 nM in B andD or as indicated in C). Nuclear extracts were analyzed for p65
byWestern immunoblotting using p65 and TBP antibodies (B), densitometry
was performed, and p65/TBP ratios were calculated (n  3, representative
results shown) or TransAM p65 ELISA (C) (* versus control, # versus agonist).
Data are representative of two independent experiments performed in trip-
licate.D, IL-8 levels were quantified in supernatants and normalized for trans-
fection efficiency. * versus unstimulated cells, # versus pCDNA3. Assays were
performed in triplicate (n 2).
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generating soluble TGF. TGF is synthesized as a precursor
membrane-bound protein. The mature TGF protein is
cleaved from the membrane-bound form to allow binding to
EGFR (29). Previously TGF has been implicated as a keymedi-
ator of EGFR activation via NE in mucin secretion (14, 16).
Through the use of a range of EGFR ligand-neutralizing anti-
bodies, we demonstrated that TGF is also the key ligand
involved in NE induction of IL-8 via EGFR in 16HBE14o- cells
in this study. This is likely to be of particular importance in the
CF lung where it is known that levels of TGF, but not EGFR,
are increased (30). Our findings complement thework of others
studying the mechanism by which NE induces mucin gene
expression in the NCI-H292 mucoepidermoid epithelial cell
line (14, 16, 22), withNE signaling via PKC-duox1-ROS-TACE-
EGFR prior to downstream signaling via EGFR.
It has been demonstrated in a TACE/ cell line that EGFR
activation can still occur indicating that enzymes sharing
redundancywithTACE can cause EGFR activation (23). Indeed
it is known that a number of proteases other than TACE are
capable of controlling ectodomain shedding of membrane-
bound factors that are members of the TNF family (31). With
this as background, we examined the possibility that othermet-
alloproteases can participate in NE-induced IL-8 production
via EGFR. We noted the presence of a high molecular weight
gelatinase present in NE-treated bronchial epithelial cell
supernatants. This activity was significant when compared
with the relative activities of other gelatinases in the samples
assayed. Previous studies using epithelial and other cell lines
have reported the presence of high molecular weight gelati-
nases evident on zymograms (32–34) thought to represent
MMP-9 dimers. We tested this using non-reducing PAGE and
Western blot analysis and failed to detect immunoreactive sig-
nals forMMP-9 above 175 kDa. Casein zymography of the sam-
ples indicated caseinase activity in NE-treated bronchial epi-
thelial cell supernatants at the molecular weight similar to the
gelatinaseactivity, indicatingdual activity fromthis enzyme.Using
an antibody against meprin alpha, an epithelial-derived metallo-
protease with dual caseinase and gelatinase activity (39) we con-
firmed that the highmolecular weight NE-induced activity in our
samples was indeed meprin alpha (25). Indeed, the concept of a
serine protease activating ametalloprotease, and thus EGFR is not
unprecedented given the recent report by Rafiq et al. (40) describ-
ing cathepsin G regulation of EGF shedding in cardiomyocytes.
Meprin is a zinc endopeptidase belonging to the astacin
family, which is composed of either homo- or heterodimers of
meprin alpha, termed meprin A, or homodimers of meprin
beta, termed meprin B. Meprin expression has been detected
on a variety of epithelial cells (41–43), salivary glands (44), leu-
kocytes (45), in certain cancer cells and tumor tissues (46–48)
andmore recently in epidermis (27).Meprins have the ability to
cleave growth factors and cytokines (49, 50) and in the past
were shown to have the ability to cleave TGF- on renal
microvillar membranes (51). We have shown meprin alpha,
similar to TACE, is capable of causing TGF release in bron-
chial epithelial cell and suggest that in 16HBE14o- cells
meprin alpha plays a key role in NE-induced IL-8 expression
given that actinonin and meprin alpha siRNA could both
inhibit induction of IL-8 by NE in these cells. In other cell
types redundancy may exist between meprin alpha and
TACE. These two proteases are closely related and the TACE
inhibitor Ro 32–7315 is known to also inhibit meprin alpha
(37).
Meprin is a proenzyme requiring activation by removal of its
N-terminal pro-peptide. In the gut trypsin is believed to per-
form this function (25). However, other activating proteases are
likely to exist in vivo, since trypsin is not expressed in all
meprin-expressing tissues. For example, plasmin has been
shown to process pro-meprin alpha in a cell culture model of
colorectal cancer (25) and kallikrein-related peptidase 4 acti-
vates meprin  (27). Here we report for the first time that NE
has the potential to process promeprin alpha in bronchial epi-
thelial cells suggesting that this process may occur in vivo at
sites associated with a high NE burden. Our animal and human
studies support this. NE knock-out mice produced less meprin
alpha compared with wild-type mice following intratracheal
instillation with Ps. aeruginosa. Our clinical data support this
and showed that highNE levels inCFBALF correlatedwell with
meprin alpha activity.
Previously, we have implicated the TLR4-Mal/MyD88-
IRAK-NFB pathway in NE-induced IL-8 expression in
16HBE14o- cells (11–13, 28). The data presented here nowpro-
vide direct evidence that EGFR and TLR4 engage in cross-talk
not only in an overexpression system but also in human bron-
chial epithelial cells to activate intracellular signals leading to a
change in IL-8 gene expression. Our evidence implicates both
EGFR andTLR4 asmembers of anNE-activated signaling com-
plex, withMyD88 participating in signaling leading to IL-8 pro-
duction. We show that meprin alpha can activate NFB in a
MyD88-dependent fashion and suggest that in response to NE,
meprin alpha and/or other metalloproteases generate EGFR
ligands that can then signal via EGFR and TLR4 to NFB acti-
vation via the MyD88 pathway. Cross-talk between EGFR and
IL-1R, a member of the IL-1R/TLR family, has previously been
reported in human keratinocytes (53), while a role for TLR4 in
EGFR trans-activation has also been reported (54). Our previ-
ous studies have demonstrated TGF and EGFR involvement
in TLR2-, TLR4-, and TLR9-mediatedmucin expression (52), a
phenomenon that is supported by the observations of Koff et al.
(20). Further evidence is emerging, from studies in tissues other
than the lung, of TLR/EGFR co-operativity suggesting a
broader role for both receptors in orchestrating cellular
responses to trans-activating signals.
In summary, this study has demonstrated the previously
unreported presence of meprin alpha, in human bronchial epi-
thelial cells. Our data highlight meprin as a new target of NE
with important functional effects and emphasizes the key role
of NE as a primary therapeutic target for inflammatory lung
disease including CF.
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